{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T10:28:11Z","timestamp":1776508091997,"version":"3.51.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2001,2]]},"DOI":"10.1023\/a:1006432012394","type":"journal-article","created":{"date-parts":[[2002,12,21]],"date-time":"2002-12-21T21:03:28Z","timestamp":1040504608000},"page":"13-20","source":"Crossref","is-referenced-by-count":11,"title":["Phase I Study of Irofulven (MGI 114), an Acylfulvene Illudin Analog, in Patients with Acute Leukemia"],"prefix":"10.1007","volume":"19","author":[{"given":"Francis","family":"Giles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Kornblau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elihu","family":"Estey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Kwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Murgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"314864_CR1","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/(SICI)1097-0142(19971201)80:11+<2176::AID-CNCR2>3.0.CO;2-G","volume":"80","author":"E Estey","year":"1997","unstructured":"Estey E, deLima M, Strom S, Pierce S, Freireich EJ, Keating MJ: Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D. Anderson Cancer Center. Cancer 80: 2176\u20132180, 1997","journal-title":"Cancer"},{"issue":"Suppl1","key":"314864_CR2","first-page":"S54","volume":"12","author":"EJ Freireich","year":"1998","unstructured":"Freireich EJ: Four decades of therapy for AML. Leukemia, 12 Suppl 1: S54\u201356, 1998","journal-title":"Leukemia"},{"key":"314864_CR3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-4613-1261-1_13","volume":"84","author":"JE Cortes","year":"1996","unstructured":"Cortes JE, Kantarjian H, Freireich EJ: Acute lymphocytic leukemia: a comprehensive review with emphasis on biology and therapy. Cancer Treat Res 84: 291\u2013323, 1996","journal-title":"Cancer Treat Res"},{"key":"314864_CR4","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/(SICI)1097-0142(19971201)80:11+<2215::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"EJ Freireich","year":"1997","unstructured":"Freireich EJ, Keating MJ: Conclusions regarding leukemia long-term survival. Cancer 80: 2215\u20132217, 1997","journal-title":"Cancer"},{"key":"314864_CR5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000227700","volume":"54","author":"EJ Freireich","year":"1997","unstructured":"Freireich EJ: The road to the cure of acute lymphoblastic leukemia: a personal perspective. Oncology 54: 265\u2013269, 1997","journal-title":"Oncology"},{"key":"314864_CR6","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","volume":"90","author":"E Estey","year":"1997","unstructured":"Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M: Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia {AML}) on outcome of AML-type chemotherapy. Blood 90: 2969\u20132977, 1997","journal-title":"Blood"},{"issue":"Suppl1","key":"314864_CR7","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0145-2126(98)00039-3","volume":"22","author":"BD Cheson","year":"1998","unstructured":"Cheson BD: Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res 22Suppl 1: S17\u201321, 1998","journal-title":"Leuk Res"},{"key":"314864_CR8","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","volume":"86","author":"S Sacchi","year":"1999","unstructured":"Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ, Talpaz M: Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86: 2632\u20132641, 1999","journal-title":"Cancer"},{"key":"314864_CR9","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/sj.leu.2401141","volume":"12","author":"K Stahnke","year":"1998","unstructured":"Stahnke K, Boos J, Bender-Gotze C, Ritter J, Zimmermann M, Creutzig U: Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 12: 1534\u20131538, 1998","journal-title":"Leukemia"},{"key":"314864_CR10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-2141.1997.3493163.x","volume":"99","author":"JM Chessels","year":"1997","unstructured":"Chessels JM, Swansbury GJ, Reeves B, Bailey CC, Richards SM: Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 99: 93\u2013100, 1997","journal-title":"Br J Haematol"},{"key":"314864_CR11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1073\/pnas.36.5.300","volume":"36","author":"M Anchel","year":"1950","unstructured":"Anchel M, Hervey A, Robbins WJ: Antibiotic substances from Basidomycetes. VII. Clitocybe iludens. Proc Natl Acad Sci USA 36: 30\u201336, 1950","journal-title":"Proc Natl Acad Sci USA"},{"key":"314864_CR12","first-page":"3186","volume":"47","author":"MJ Kelner","year":"1987","unstructured":"Kelner MJ, McMorris TC, Beck WT, Zamora JM, Taetle R: Preclinical evaluation of illudins as anticancer agents. Cancer Res 47: 3186\u20133189, 1987","journal-title":"Cancer Res"},{"key":"314864_CR13","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/jnci\/82.19.1562","volume":"82","author":"MJ Kelner","year":"1990","unstructured":"Kelner MJ, McMorris TC, Taetle R: Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity. J Natl Cancer Inst 82: 1562\u20131565, 1990","journal-title":"J Natl Cancer Inst"},{"key":"314864_CR14","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0006-2952(00)00254-9","volume":"59","author":"BA Woynarowska","year":"2000","unstructured":"Woynarowska BA, Woynarowski JM, Herzig MC, Roberts K, Higdon AL, MacDonald JR: Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). Biochem Pharmacol 59: 1217\u20131226, 2000","journal-title":"Biochem Pharmacol"},{"key":"314864_CR15","first-page":"4936","volume":"55","author":"MJ Kelner","year":"1995","unstructured":"Kelner MJ, McMorris TC, Estes L, Starr RJ, Rutherford M, Montoya M, Samson KM, Taetle R: Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicasedeficient cells. Cancer Res 55: 4936\u20134940, 1995","journal-title":"Cancer Res"},{"key":"314864_CR16","first-page":"233","volume":"13","author":"A Murgo","year":"1999","unstructured":"Murgo A, Cannon DJ, Blatner G, Cheson BD: Clinical trials referral resource. Clinical trials of MGI-114. Oncology (Huntingt) 13: 233, 237-238, 1999","journal-title":"Oncology (Huntingt)"},{"key":"314864_CR17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0006-2952(94)90113-9","volume":"48","author":"MJ Kelner","year":"1994","unstructured":"Kelner MJ, McMorris TC, Estes L, Rutherford M, Montoya M, Goldstein J, Samson K, Starr R, Taetle R: Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. Biochem Pharmacol 48: 403\u2013409, 1994","journal-title":"Biochem Pharmacol"},{"key":"314864_CR18","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0006-2952(97)00321-3","volume":"54","author":"JM Woynarowski","year":"1997","unstructured":"Woynarowski JM, Napier C, Koester SK, Chen SF, Troyer D, Chapman W, MacDonald JR: Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol 54: 1181\u20131193, 1997","journal-title":"Biochem Pharmacol"},{"key":"314864_CR19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0968-0896(99)00016-4","volume":"7","author":"TC McMorris","year":"1999","unstructured":"McMorris TC: Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug. Bioorg Med Chem 7: 881\u2013886, 1999","journal-title":"Bioorg Med Chem"},{"key":"314864_CR20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33: 451\u2013458, 1976","journal-title":"Br J Haematol"},{"key":"314864_CR21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/10428190009148395","volume":"36","author":"J Cortes","year":"2000","unstructured":"Cortes J, Estey E, Beran M, O'Brien S, Giles FJ, Koller C, Keating MJ, Kantarjian HM: Cyclophosphamide, ara-C, and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymph 36: 479\u2013484, 2000","journal-title":"Leuk Lymph"},{"key":"314864_CR22","first-page":"1594","volume":"87","author":"TC McMorris","year":"1965","unstructured":"McMorris TC, Anchel M: Fungal metabolites. The structure of the novel sesquiterpenoids Illudin-S and-M. J Am Chem 87: 1594\u20131600, 1965","journal-title":"The structure of the novel sesquiterpenoids Illudin-S and-M. J Am Chem"},{"key":"314864_CR23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00210787","volume":"14","author":"MJ Kelner","year":"1996","unstructured":"Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R: Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 14: 161\u2013167, 1996","journal-title":"Invest New Drugs"},{"key":"314864_CR24","first-page":"279","volume":"57","author":"JR MacDonald","year":"1997","unstructured":"MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD: Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 57: 279\u2013283, 1997","journal-title":"Cancer Res"},{"key":"314864_CR25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0959-8049(98)00033-1","volume":"34","author":"MJ Kelner","year":"1998","unstructured":"Kelner MJ, McMorris TC, Estes L, Samson KM, Bagnell RD, Taetle R: Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1\/gp170 metastatic MV522 lung carcinoma xenograft. Eur J Cancer 34: 908\u2013913, 1998","journal-title":"Eur J Cancer"},{"key":"314864_CR26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0305-7372(98)90056-1","volume":"24","author":"E Reed","year":"1998","unstructured":"Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24: 331\u2013344, 1998","journal-title":"Cancer Treat Rev"},{"key":"314864_CR27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev.ge.29.120195.000441","volume":"29","author":"A Sancar","year":"1995","unstructured":"Sancar A: DNA repair in humans. Annu Rev Genet 29: 69\u2013105, 1995","journal-title":"Annu Rev Genet"},{"key":"314864_CR28","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/jnci\/84.19.1512","volume":"84","author":"M Dabholkar","year":"1992","unstructured":"Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512\u20131517, 1992","journal-title":"J Natl Cancer Inst"},{"key":"314864_CR29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1172\/JCI117388","volume":"94","author":"M Dabholkar","year":"1994","unstructured":"Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703\u2013708, 1994","journal-title":"J Clin Invest"},{"key":"314864_CR30","first-page":"1261","volume":"55","author":"MD Dabholkar","year":"1995","unstructured":"Dabholkar MD, Berger MS, Vionnet JA, Egwuagu C, Silber JR, Yu JJ, Reed E: Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res 55: 1261\u20131266, 1995","journal-title":"Cancer Res"},{"key":"314864_CR31","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/carcin\/14.10.2177","volume":"14","author":"KB Lee","year":"1993","unstructured":"Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E: Cisplatin sensitivity\/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 14: 2177\u20132180, 1993","journal-title":"Carcinogenesis"},{"key":"314864_CR32","first-page":"201a","volume":"19","author":"G Megason","year":"2000","unstructured":"Megason G, Weitman S, Blaney S, Winick N, Kuhn J, Pullen J, Bernstein M: A trial of 6-Hydroxymetylacylfulvene (MGI-114) in children with solid tumors, a Pediatric Oncology Group Phase I Cooperative Agreement Study. J Clin Oncol, Proc ASCO 19: 201a, 2000","journal-title":"J Clin Oncol, Proc ASCO"},{"key":"314864_CR33","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1023\/A:1018889904839","volume":"42","author":"TM Shehab","year":"1997","unstructured":"Shehab TM, Kaminski MS, Lok AS: Acute liver failure due to hepatic involvement by hematologic malignancy. Dig Dis Sci 42: 1400\u20131405, 1997","journal-title":"Dig Dis Sci"},{"key":"314864_CR34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.leu.2401611","volume":"14","author":"MJ Kelner","year":"2000","unstructured":"Kelner MJ, McMorris TC, Estes L, Samson KM, Trani NA, MacDonald JR: Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan. Leukemia 14: 136\u2013141, 2000","journal-title":"Leukemia"},{"key":"314864_CR35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10428199809057611","volume":"31","author":"M Beran","year":"1998","unstructured":"Beran M, Estey E, O'Brien SM, Giles FJ, Koller CA, Kornblau S, Keating M, Kantarjian HM: Results of topotecan singleagent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 31: 521\u2013531, 1998","journal-title":"Leuk Lymphoma"},{"key":"314864_CR36","first-page":"26","volume":"35","author":"M Beran","year":"1998","unstructured":"Beran M, Kantarjian H: Topotecan in the treatment of hematologic malignancies. Semin Hematol 35: 26\u201331, 1998","journal-title":"Semin Hematol"},{"key":"314864_CR37","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.V88.7.2473.bloodjournal8872473","volume":"88","author":"M Beran","year":"1996","unstructured":"Beran M, Kantarjian H, O'Brien S, Koller C, al-Bitar M, Arbuck S, Pierce S, Moore M, Abbruzzese JL, Andreeff M, Keating M, Estey E: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88: 2473\u20132479, 1996","journal-title":"Blood"},{"key":"314864_CR38","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood.V81.5.1146.1146","volume":"81","author":"HM Kantarjian","year":"1993","unstructured":"Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ et al.: Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81: 1146\u20131151, 1993","journal-title":"Blood"},{"key":"314864_CR39","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.1994.12.10.2193","volume":"12","author":"EK Rowinsky","year":"1994","unstructured":"Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH: Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12: 2193\u20132203, 1994","journal-title":"J Clin Oncol"},{"key":"314864_CR40","first-page":"1921","volume":"2","author":"EK Rowinsky","year":"1996","unstructured":"Rowinsky EK, Kaufmann SH, Baker SD, Miller CB, Sartorius SE, Bowling MK, Chen TL, Donehower RC, Gore SD: A Phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia. Clin Cancer Res 2: 1921\u20131930, 1996","journal-title":"Clin Cancer Res"},{"key":"314864_CR41","first-page":"3","volume":"36","author":"M Beran","year":"1999","unstructured":"Beran M, Kantarjian H: Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Semin Hematol 36: 3\u201310, 1999","journal-title":"Semin Hematol"},{"key":"314864_CR42","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","volume":"17","author":"M Beran","year":"1999","unstructured":"Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17: 2819\u20132830, 1999","journal-title":"J Clin Oncol"},{"key":"314864_CR43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1023\/A:1006271618635","volume":"17","author":"N Vey","year":"1999","unstructured":"Vey N, Kantarjian H, Beran M, O'Brien S, Cortes J, Koller C, Estey E: Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized Phase I\/II study. Invest New Drugs 17: 89\u201395, 1999","journal-title":"Invest New Drugs"},{"key":"314864_CR44","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1349-7006.1995.tb02468.x","volume":"86","author":"I Mitsui","year":"1995","unstructured":"Mitsui I, Kumazawa E, Hirota Y, Aonuma M, Sugimori M, Ohsuki S, Uoto K, Ejima A, Terasawa H, Sato K: A new watersoluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 86: 776\u2013782, 1995","journal-title":"Jpn J Cancer Res"},{"key":"314864_CR45","first-page":"731","volume":"6","author":"N Vey","year":"2000","unstructured":"Vey N, Giles F, Kantarjian H, Smith TL, Beran M, Jeha S: The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clin Cancer Res 6: 731\u2013736, 2000","journal-title":"Clin Cancer Res"},{"key":"314864_CR46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V88.2.756.bloodjournal882756","volume":"88","author":"E Estey","year":"1996","unstructured":"Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M: A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 88: 756, 1996 Address for offprints: Francis J. Giles, Department of Leukemia, Box 61, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030\u20134095, USA; E-mail: fgiles@mdanderson.org","journal-title":"Blood"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006432012394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1006432012394\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006432012394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:54:33Z","timestamp":1753818873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1006432012394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["314864"],"URL":"https:\/\/doi.org\/10.1023\/a:1006432012394","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2]]}}}